Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Eribulin + Pyrotinib for HER2-positive advanced breast cancer after taxane and trastuzumab failure
ChiCTR2000038832Phase 4Recruiting
- Sponsor
- The Fourth Hospital of Hebei Medical University
- Start
- Sep 2020
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of eribulin and pyrotinib in breast cancer, sponsored by The Fourth Hospital of Hebei Medical University. Primary endpoint: Progression-free survival. Started Sep 2020; status: recruiting.
02
Drugs
eribulinpyrotinib
03
Conditions
breast cancer
Beyond the preview
Go deeper on ChiCTR2000038832.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2000038832.